المؤلفون: Magdalena Trzeciak, Lidia Rudnicka, Petr Arenberger, Burhan Engin, Andrey L'vov, Sibel Alper, Erkan Alpsoy, Nina Benáková, Svetlana Bobko, Murat Borlu, Magdalena Czarnecka-Operacz, Olga Elisyutina, Tulin Ergun, Ilgen Ertam, Elena Fedenko, Olga Filipovská, Daria Fomina, Aida Gadzhigoroeva, Martina Kojanová, Aleksandra Lesiak, Anna Michenko, Nikolay Murashkin, Witold Owczarek, Esen Özkaya, Zuzana Plzáková, Adam Reich, Marie Selerova, Burcu A. Gurbuz

المصدر: Frontiers in Medicine, Vol 11 (2024)

مصطلحات موضوعية: atopic dermatitis, disease burden, management, treatment, moderate-to-severe AD, Medicine (General), R5-920

الوصف: BackgroundThere is limited insight into the current disease burden and everyday clinical management of moderate-to- severe AD in Poland, Czechia, Russia, and Turkiye. Therefore, this study aimed to get information-driven insights regarding the current disease burden and clinical management of patients with moderate-to-severe AD with common and differentiating aspects of the patient journey and establish a consensus.MethodsIn this modified 2-round Delphi panel, 133 questions were asked in total to 27 dermatologists. A consensus was achieved when 70% of the panel members strongly agreed or agreed (or strongly disagreed or disagreed) with an item. Statements with

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fmed.2024.1402493/fullTest; https://doaj.org/toc/2296-858XTest

الوصول الحر: https://doaj.org/article/fef9177ae74e42a89fb6d7ef9ccc7290Test

المؤلفون: Spyridon Gkalpakiotis, Martina Kojanová, Jorga Fialová, Petra Cetkovská, Vladimír Vašků, Yvetta Vantuchová, Alena Machovcová, Petra Gkalpakioti, Pavla Hrdá, Petr Arenberger

المصدر: Dermatology and Therapy, Vol 14, Iss 1, Pp 115-130 (2023)

مصطلحات موضوعية: Brodalumab, Biological therapy, LIBERO, Non-interventional study, Plaque psoriasis, Real-world evidence, Dermatology, RL1-803

الوصف: Abstract Introduction Psoriasis is a chronic, immune-mediated inflammatory skin disease. Despite the availability of several therapies, many patients affected by this disease remain untreated, do not have adequate response, or suffer from treatment-related toxic effects. It has been shown that the interleukin (IL)-17 pathway plays a key role in the immunopathogenesis of psoriasis. Brodalumab, the first human monoclonal IgG2 antibody that selectively binds to subunit A of the human IL-17 receptor, blocking interactions with a number of cytokines of the IL-17 family, has confirmed fast onset of action, high complete clearance rates, and sustained efficacy. Nevertheless, there is only a limited amount of published real-world evidence (RWE) data. Methods This was an open-label, multicenter, real-world, prospective, non-interventional, non-controlled (single-arm) observational study (LIBERO-CZ) assessing the management of moderate to severe psoriasis with brodalumab in daily practice for up to 52 weeks of treatment. Results Fifty-four patients (70.4% male, mean age 46.9 ± 13.4 years, weight 95.6 ± 22.7 kg, disease duration 18.6 ± 12.7 years) were enrolled and included in the final analysis. Forty-nine of the patients completed the study and five discontinued prematurely; 51.8% of all the enrolled patients were biologic-naïve. At baseline, 28% patients were classified as severe (psoriasis area severity index (PASI) ≥ 20). Overall, the mean PASI decreased by 15.6 from 16.1 (± 5.0) at baseline to 0.5 (± 1.2) at the last visit. The primary endpoint of an absolute PASI ≤ 3 at week 12 (as observed analysis) was achieved by 95.9% of patients. The static Physician’s Global Assessment (sPGA) success (defined as clear = 0 and almost clear = 1) at week 52 was achieved by 92.1% of patients. PASI 75, PASI 90, and PASI 100 were achieved by 98.0%, 87.8%, and 75.5% of patients, respectively, after approximately 52 weeks of treatment. The study also recorded very positive results concerning patient-reported outcomes. Conclusions LIBERO-CZ confirms the fast onset and high clearance rates of brodalumab in real life in both biologic-naïve and biologic-experienced patients.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2193-8210Test; https://doaj.org/toc/2190-9172Test

الوصول الحر: https://doaj.org/article/df314a346ccb414f84225458fc42801fTest

المؤلفون: Lidia Rudnicka, Magdalena Trzeciak, Erkan Alpsoy, Petr Arenberger, Sibel Alper, Nina Benáková, Svetlana Bobko, Murat Borlu, Magdalena Czarnecka Operacz, Burhan Engin, Tülin Ergun, Ilgen Ertam Sağduyu, Olga Filipovská, Aida Gadzhigoroeva, Martina Kojanová, Aleksandra Lesiak, Anna Michenko, Nikolay Murashkin, Nahide Onsun, Witold Owczarek, Zuzana Plzakova, Adam Reich, Marie Selerová, Burcu Aybike Gürbüz

المصدر: Frontiers in Medicine, Vol 11 (2024)

مصطلحات موضوعية: alopecia areata, disease burden, diagnosis, treatment, clinical management, Medicine (General), R5-920

الوصف: ObjectivesThis study aims to update the understanding of Alopecia Areata (AA) in Poland, Czechia, Russia, and Türkiye, focusing on the disease burden, clinical management, and patient journey. It seeks to establish a consensus on optimal management strategies for AA in these regions.MethodsA modified 2-round Delphi panel was conveyed with 23 Dermatologists (Russia; 4, Türkiye; 7, Poland; 6, and Czechia; 6). The Delphi questionnaire consisted of 61 statements and 43 questions designed to obtain an overall understanding of the perception and acceptance of available information regarding the care of patients with alopecia areata.ResultsThe study revealed that moderate-to-severe AA significantly impacts patients’ and their families’ QoL, consistent with previous studies. AA was found to cause more substantial impairment when additional lesions appeared in visible areas besides the scalp. Work and productivity impairment were notably higher in adults with moderate-to-severe AA. Diagnostic consensus highlighted the importance of skin biopsies and trichoscopy, while the need for more practical severity scoring systems was emphasized. Current treatments, including topical therapies, corticosteroids, and systemic immune modifiers, were deemed insufficient, highlighting the unmet medical need.ConclusionThe Delphi study underscores a significant disease burden and unmet medical needs in patients with moderate-to-severe AA. It highlights the necessity of access to novel treatments and further research to develop more effective therapies with a tolerable safety profile. The findings align with global research, emphasizing the psychosocial impact of AA and the need for standardized, effective treatment protocols.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fmed.2024.1353354/fullTest; https://doaj.org/toc/2296-858XTest

الوصول الحر: https://doaj.org/article/4f0456de4f014eb2a78dd950a5b58a69Test

المؤلفون: Linda Stein Gold, Andreas Pinter, April Armstrong, Matthias Augustin, Petr Arenberger, Neil Bhatia, Morten Praestegaard, Lars Iversen, Adam Reich

المصدر: Dermatology and Therapy, Vol 13, Iss 9, Pp 2031-2044 (2023)

مصطلحات موضوعية: Betamethasone dipropionate, Calcipotriene, Cream, Gel, PAD Technology™, Psoriasis, Dermatology, RL1-803

الوصف: Abstract Introduction Psoriasis ranges from mild to severe with the majority of patients having mild disease. Mild to moderate disease is often treated with topical therapies while photo-, oral, and biologic therapies are generally reserved for moderate-to-severe disease. There is a strong scientific rationale for the combination of calcipotriene (CAL) and betamethasone dipropionate (BDP) with respect to mode of action, efficacy, and safety and CAL/BDP has shown an inhibitory effect on key pathogenic cytokines in psoriasis including tumor necrosis factor-α, interleukin (IL)-17, and IL-23. Methods The objective of this pooled post hoc analysis is to investigate the efficacy of CAL/BDP polyaphron dispersion (PAD)-cream in subgroups of patients with moderate-to-severe psoriasis from two completed phase 3 studies conducted in the USA and Europe. Results The proportion of patients achieving Physician Global Assessment (PGA) treatment success as well as a modified Psoriasis Area and Severity Index (mPASI)75 response was higher in the subgroup with a body surface area > 10% and mPASI > 10 and Dermatology Life Quality Index > 10 at baseline compared to the overall patient population. Furthermore, the numerical difference in treatment efficacy between CAL/BDP PAD-cream and CAL/BDP topical suspension/gel increased in patient subgroups with higher baseline severity. Similar patterns were shown for the patient-reported outcomes. Conclusion In this subgroup analysis, patients who had higher disease severity at baseline achieved greater efficacy than the total patient population when treated with 8 weeks of CAL/BDP PAD-cream as compared to a currently marketed active comparator. Additionally, as indicated by this analysis, CAL/BDP PAD-cream treatment may also be more convenient and less greasy, which may reduce the burden of daily treatment and improve adherence to therapy. Trial Registration NCT03308799 and NCT03802344.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2193-8210Test; https://doaj.org/toc/2190-9172Test

الوصول الحر: https://doaj.org/article/3bfde76e354a4313a41209279070597eTest

المؤلفون: Marjolein de Bruin-Weller, Andrew E. Pink, Annalisa Patrizi, Ana M. Gimenez-Arnau, Tove Agner, Pierre-Paul Roquet-Gravy, Silvia M. Ferrucci, Petr Arenberger, Ake Svensson, Marie L.A Schuttelaar, Audrey Nosbaum, Shyamalie Jayawardena, Elena Rizova, Marius Ardeleanu, Laurent Eckert, Zafer E. Ozturk

المصدر: Journal of Dermatological Treatment, Vol 32, Iss 2, Pp 164-173 (2021)

مصطلحات موضوعية: atopic dermatitis, systemic therapy, patient-reported outcomes, quality of life, Dermatology, RL1-803

الوصف: Background Insights into the real-world treatment paradigm and long-term burden of atopic dermatitis (AD) are needed to inform clinical and health policy decisions. Methods The prospective, observational EUROSTAD study enrolled adults with moderate-to-severe AD starting or switching systemic therapy (51 sites in 10 European countries). We report the baseline characteristics, treatment patterns, and outcomes of these patients using descriptive statistics. Results A 12-month enrollment period of EUROSTAD was completed and 308 patients were enrolled: average age 37 years, AD duration 25 years, 43% were female. Most patients reported use of systemic therapy (93%) and ≥1 atopic comorbidity (82%). Mean [standard deviation] disease severity/burden measures were high: Investigator’s Global Assessment (3.1 [0.8]), Eczema Area and Severity Index (16.2 [10.9]), Peak Pruritus Numerical Rating Scale (5.5 [2.5]), sleep impairment Visual Analog Scale (49.8 [31.6]) scores, and time lost from work (4.1 [13.7] days/year) or usual activities (16.8 [38.7] days/year). Most patients showed borderline or clinical levels of anxiety (59%) and/or depression (63%) using the Hospital Anxiety and Depression Scale. Conclusions Adults with moderate-to-severe AD starting/switching systemic treatment enrolled in EUROSTAD have a high burden of longstanding disease despite continuous use of topical drugs, emollients, and systemic therapies.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/0954-6634Test; https://doaj.org/toc/1471-1753Test

الوصول الحر: https://doaj.org/article/d943e6c77a754d7d8ed0a7b518856532Test

المؤلفون: Anna Marsakova, Avraham Kudish, Spyridon Gkalpakiotis, Irmgard Jahn, Petr Arenberger, Marco Harari

المصدر: Journal of Dermatological Treatment, Vol 31, Iss 7, Pp 711-715 (2020)

مصطلحات موضوعية: atopic dermatitis, children, dead sea climatotherapy, scorad, follow-up, Dermatology, RL1-803

الوصف: The aim of this study was to compare long-term results of 4 weeks Dead Sea climatotherapy at the Deutsches Medizinisches Zentrum, Israel to those obtained by classical topical treatment for moderate-to-severe atopic dermatitis. Seventy-two children from the Czech Republic were divided into three groups of 24 and treated during three periods (March 2014, October 2014 and March 2015) with gradually increasing sun exposure during 28 consecutive days. Forty-four children were treated with steroid creams at the Department of Dermatovenereology, Third Faculty of Medicine, Charles University and University Hospital of Kralovske Vinohrady, Prague, Czech Republic. The primary outcome was the change in the SCORing Atopic Dermatitis (SCORAD) index, recorded after 1 month of treatment (immediately after DSC) and 3, 6, 9, 12, and 18 months later in Prague. The mean SCORAD improvement was 87.5 ± 13.4% after 4 weeks at the Dead Sea and 86.1 ± 11.3% after 1 month of treatment with steroid creams in the Czech Republic. All 44 patients treated in Prague participated in this 18-month follow-up study, whereas only 47 patients (65.3%) after DSC treatment. Good clinical results were maintained in both groups and mean SCORAD values were stable and low, around 5.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/0954-6634Test; https://doaj.org/toc/1471-1753Test

الوصول الحر: https://doaj.org/article/a0d124b2002e4e0e86f0d313c544238cTest

المؤلفون: James Larkin, Jeffrey Weber, Victoria Atkinson, Michael Millward, Ivan Marquez-Rodas, Luis de la Cruz-Merino, Helen Gogas, Paolo A Ascierto, Anna Maria Di Giacomo, Veerle de Pril, Vanna Chiarion-Sileni, Stephane Dalle, Leslie Fecher, Ana Arance, Jean-Jacques Grob, Nikhil I Khushalani, Michele Del Vecchio, Mario Mandala, C Lance Cowey, Michael Schenker, Petr Arenberger, Maurice Lobo

المصدر: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)

مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://jitc.bmj.com/content/9/8/e003188.fullTest; https://doaj.org/toc/2051-1426Test

الوصول الحر: https://doaj.org/article/c281f8a682984c818531f79c5352985aTest

المؤلفون: Elizabeth Adenubiova, Petr Arenberger, Petra Gkalpakioti, Monika Arenbergerova, Jitka Jircikova, Tomas Dolezal, Spyridon Gkalpakiotis

المصدر: Journal of Dermatological Treatment, Vol 29, Iss 6, Pp 579-582 (2018)

مصطلحات موضوعية: psoriasis, adalimumab, long-term efficacy, Dermatology, RL1-803

الوصف: Background: Adalimumab therapy has an established record of high efficacy in psoriasis treatment. However, only a limited number of studies have investigated long-term results in clinical practice. Objectives: To evaluate the effectiveness and safety of adalimumab in a center for biological therapy in the Czech Republic. Methods: Retrospectively, we analyzed 90 patients with moderate to severe psoriasis who were treated with adalimumab between 2008 and 2016. The proportion of patients achieving PASI75, 90, and 100 after 3, 6, 12, 18, 24, 30, and 36 months was determined. Results: The mean period of treatment was 4.4 years (maximum duration reached was 8.6 years). PASI75 was observed in 85.6% of patients after 3 months, PASI90 in 50%, and PASI100 in 23.3%. Throughout the 3-year analysis, PASI90 was persistent in 91.4% and PASI100 in 51.7%. The majority of patients who reached PASI100 showed a trend to maintain the response in the long-term follow-up. No safety issues were identified. Conclusions: Adalimumab is effective and safe in the long-term treatment of psoriatic patients in daily clinical practice. Once patients achieved PASI100, they tended to remain stable in treatment.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/0954-6634Test; https://doaj.org/toc/1471-1753Test

الوصول الحر: https://doaj.org/article/82ad18baf2844199815703b946640ee9Test

المؤلفون: Emanuel C Marques, Spyridon Gkalpakiotis, Monika Arenbergerová, Petr Arenberger

المصدر: Indian Journal of Dermatology, Vol 67, Iss 5, Pp 628-628 (2022)

مصطلحات موضوعية: Dermatology, RL1-803

وصف الملف: electronic resource

العلاقة: http://www.e-ijd.org/article.asp?issn=0019-5154;year=2022;volume=67;issue=5;spage=628;epage=628;aulast=MarquesTest; https://doaj.org/toc/0019-5154Test; https://doaj.org/toc/1998-3611Test

الوصول الحر: https://doaj.org/article/417ef85c5b41446f84aa893824adc4f7Test

المؤلفون: Spyridon Gkalpakiotis, Petr Arenberger, Eva Sticova, Ivana Karlova, Monika Arenbergerova

المصدر: Indian Journal of Dermatology, Vol 65, Iss 1, Pp 83-84 (2020)

مصطلحات موضوعية: Dermatology, RL1-803

وصف الملف: electronic resource

العلاقة: http://www.e-ijd.org/article.asp?issn=0019-5154;year=2020;volume=65;issue=1;spage=83;epage=84;aulast=GkalpakiotisTest; https://doaj.org/toc/0019-5154Test; https://doaj.org/toc/1998-3611Test

الوصول الحر: https://doaj.org/article/a67587f540a8462c8272b4c96ece617fTest